AU7071598A - Diagnosis method and reagents - Google Patents
Diagnosis method and reagents Download PDFInfo
- Publication number
- AU7071598A AU7071598A AU70715/98A AU7071598A AU7071598A AU 7071598 A AU7071598 A AU 7071598A AU 70715/98 A AU70715/98 A AU 70715/98A AU 7071598 A AU7071598 A AU 7071598A AU 7071598 A AU7071598 A AU 7071598A
- Authority
- AU
- Australia
- Prior art keywords
- seq
- disease
- protein
- mutant
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 112
- 238000003745 diagnosis Methods 0.000 title claims description 25
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 252
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 209
- 210000004027 cell Anatomy 0.000 claims description 193
- 102000004169 proteins and genes Human genes 0.000 claims description 176
- 201000010099 disease Diseases 0.000 claims description 171
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 171
- 230000037433 frameshift Effects 0.000 claims description 125
- 230000035772 mutation Effects 0.000 claims description 120
- 231100000221 frame shift mutation induction Toxicity 0.000 claims description 101
- 208000024827 Alzheimer disease Diseases 0.000 claims description 92
- 108010021466 Mutant Proteins Proteins 0.000 claims description 92
- 102000008300 Mutant Proteins Human genes 0.000 claims description 92
- 102000053642 Catalytic RNA Human genes 0.000 claims description 77
- 108090000994 Catalytic RNA Proteins 0.000 claims description 77
- 108091092562 ribozyme Proteins 0.000 claims description 77
- 101100228149 Drosophila melanogaster Trl gene Proteins 0.000 claims description 67
- 241001123946 Gaga Species 0.000 claims description 67
- 239000002773 nucleotide Substances 0.000 claims description 65
- 125000003729 nucleotide group Chemical group 0.000 claims description 64
- 239000013598 vector Substances 0.000 claims description 63
- 150000007523 nucleic acids Chemical class 0.000 claims description 62
- 239000000523 sample Substances 0.000 claims description 57
- 102000039446 nucleic acids Human genes 0.000 claims description 52
- 108020004707 nucleic acids Proteins 0.000 claims description 52
- 210000001519 tissue Anatomy 0.000 claims description 40
- 230000000295 complement effect Effects 0.000 claims description 39
- 238000012217 deletion Methods 0.000 claims description 38
- 230000037430 deletion Effects 0.000 claims description 38
- 108020004414 DNA Proteins 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 33
- 206010012289 Dementia Diseases 0.000 claims description 31
- 238000001514 detection method Methods 0.000 claims description 23
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 21
- 108010050254 Presenilins Proteins 0.000 claims description 20
- 102000015499 Presenilins Human genes 0.000 claims description 20
- 239000012472 biological sample Substances 0.000 claims description 19
- 230000004770 neurodegeneration Effects 0.000 claims description 19
- -1 Big Tau Proteins 0.000 claims description 18
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 16
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 16
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 15
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 15
- 210000000349 chromosome Anatomy 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 210000001124 body fluid Anatomy 0.000 claims description 14
- 108010026424 tau Proteins Proteins 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 14
- 102000044159 Ubiquitin Human genes 0.000 claims description 13
- 108090000848 Ubiquitin Proteins 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 238000003780 insertion Methods 0.000 claims description 13
- 230000037431 insertion Effects 0.000 claims description 13
- 230000002441 reversible effect Effects 0.000 claims description 13
- 102000013498 tau Proteins Human genes 0.000 claims description 13
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims description 12
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 claims description 12
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 12
- 108010088373 Neurofilament Proteins Proteins 0.000 claims description 12
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 12
- 101150080074 TP53 gene Proteins 0.000 claims description 12
- 239000010839 body fluid Substances 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 12
- 239000002853 nucleic acid probe Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 102000008763 Neurofilament Proteins Human genes 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 108091012583 BCL2 Proteins 0.000 claims description 9
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 238000009007 Diagnostic Kit Methods 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 8
- 206010034010 Parkinsonism Diseases 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 7
- 230000002163 immunogen Effects 0.000 claims description 7
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 claims description 6
- 108090000192 Methionyl aminopeptidases Proteins 0.000 claims description 6
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 claims description 6
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 claims description 6
- 102100027974 Semaphorin-3A Human genes 0.000 claims description 6
- 108010090319 Semaphorin-3A Proteins 0.000 claims description 6
- 239000005022 packaging material Substances 0.000 claims description 6
- 230000008506 pathogenesis Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 5
- 108010025628 Apolipoproteins E Proteins 0.000 claims description 5
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 238000012163 sequencing technique Methods 0.000 claims description 5
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 4
- 208000011403 Alexander disease Diseases 0.000 claims description 4
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 4
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 230000002308 calcification Effects 0.000 claims description 4
- 208000017004 dementia pugilistica Diseases 0.000 claims description 4
- 210000000981 epithelium Anatomy 0.000 claims description 4
- 210000001652 frontal lobe Anatomy 0.000 claims description 4
- 210000004276 hyalin Anatomy 0.000 claims description 4
- 210000003000 inclusion body Anatomy 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 4
- 230000037432 silent mutation Effects 0.000 claims description 4
- 206010011659 Cutaneous amyloidosis Diseases 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 208000015413 lichen amyloidosis Diseases 0.000 claims description 3
- 238000003757 reverse transcription PCR Methods 0.000 claims 3
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 41
- 239000002502 liposome Substances 0.000 description 37
- 239000000126 substance Substances 0.000 description 34
- 125000003275 alpha amino acid group Chemical group 0.000 description 33
- 239000000463 material Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 238000003776 cleavage reaction Methods 0.000 description 21
- 230000007017 scission Effects 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 101000772905 Homo sapiens Polyubiquitin-B Proteins 0.000 description 16
- 230000000875 corresponding effect Effects 0.000 description 16
- 239000011159 matrix material Substances 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 102100030432 Polyubiquitin-B Human genes 0.000 description 13
- 238000010240 RT-PCR analysis Methods 0.000 description 13
- 210000002569 neuron Anatomy 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 108091026890 Coding region Proteins 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 102000014914 Carrier Proteins Human genes 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 11
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 108010004977 Vasopressins Proteins 0.000 description 11
- 102000002852 Vasopressins Human genes 0.000 description 11
- 230000009261 transgenic effect Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 108091008324 binding proteins Proteins 0.000 description 10
- 230000001537 neural effect Effects 0.000 description 10
- 150000003904 phospholipids Chemical class 0.000 description 10
- GAAKALASJNGQKD-UHFFFAOYSA-N LY-165163 Chemical compound C1=CC(N)=CC=C1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 GAAKALASJNGQKD-UHFFFAOYSA-N 0.000 description 9
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 9
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000005538 encapsulation Methods 0.000 description 9
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229960003726 vasopressin Drugs 0.000 description 9
- 208000037259 Amyloid Plaque Diseases 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 108700019146 Transgenes Proteins 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 210000001320 hippocampus Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 206010006895 Cachexia Diseases 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 210000005153 frontal cortex Anatomy 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000000527 sonication Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 201000010374 Down Syndrome Diseases 0.000 description 6
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 241000251131 Sphyrna Species 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 230000002123 temporal effect Effects 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 108020005544 Antisense RNA Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000011888 autopsy Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000003184 complementary RNA Substances 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000001177 retroviral effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 108091028664 Ribonucleotide Proteins 0.000 description 4
- 239000012722 SDS sample buffer Substances 0.000 description 4
- 108050003978 Semaphorin Proteins 0.000 description 4
- 102000014105 Semaphorin Human genes 0.000 description 4
- 101150037646 VP gene Proteins 0.000 description 4
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000008105 immune reaction Effects 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229960004452 methionine Drugs 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000002241 neurite Anatomy 0.000 description 4
- 210000005044 neurofilament Anatomy 0.000 description 4
- 210000002511 neuropil thread Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000002336 ribonucleotide Substances 0.000 description 4
- 125000002652 ribonucleotide group Chemical group 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 208000002109 Argyria Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 201000004813 Bronchopneumonia Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- CGYDXNKRIMJMLV-GUBZILKMSA-N Glu-Arg-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O CGYDXNKRIMJMLV-GUBZILKMSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001131829 Homo sapiens P protein Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 208000010577 Niemann-Pick disease type C Diseases 0.000 description 3
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000002306 biochemical method Methods 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 102000047119 human OCA2 Human genes 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 108010091047 neurofilament protein H Proteins 0.000 description 3
- 230000007171 neuropathology Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 101710104359 F protein Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- CTVJSFRHUOSCQQ-DCAQKATOSA-N Met-Arg-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O CTVJSFRHUOSCQQ-DCAQKATOSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 102000012412 Presenilin-1 Human genes 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 102100022033 Presenilin-1 Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102000007238 Transferrin Receptors Human genes 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 206010007625 cardiogenic shock Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000039 congener Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 238000010448 genetic screening Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000001466 metabolic labeling Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- KAICRBBQCRKMPO-UHFFFAOYSA-N phosphoric acid;pyridine-3,4-diamine Chemical compound OP(O)(O)=O.NC1=CC=NC=C1N KAICRBBQCRKMPO-UHFFFAOYSA-N 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 230000008016 vaporization Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100027831 14-3-3 protein theta Human genes 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 101150110188 30 gene Proteins 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000022099 Alzheimer disease 2 Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 description 1
- QAODJPUKWNNNRP-DCAQKATOSA-N Arg-Glu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QAODJPUKWNNNRP-DCAQKATOSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100471685 Caenorhabditis elegans ubq-2 gene Proteins 0.000 description 1
- 101800005309 Carboxy-terminal peptide Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102100032404 Cholinesterase Human genes 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 238000012287 DNA Binding Assay Methods 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 241000630665 Hada Species 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101100434309 Homo sapiens ADA gene Proteins 0.000 description 1
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000979321 Homo sapiens Neurofilament medium polypeptide Proteins 0.000 description 1
- 101100462513 Homo sapiens TP53 gene Proteins 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102100021118 Microtubule-associated protein 2 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102100024007 Neurofilament heavy polypeptide Human genes 0.000 description 1
- 101710109612 Neurofilament medium polypeptide Proteins 0.000 description 1
- 102100023055 Neurofilament medium polypeptide Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006588 Pleural Empyema Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102100033504 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- OGFYGJDCQZJOFN-UHFFFAOYSA-N [O].[Si].[Si] Chemical compound [O].[Si].[Si] OGFYGJDCQZJOFN-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 description 1
- DAPUDVOJPZKTSI-UHFFFAOYSA-L ammonium nickel sulfate Chemical compound [NH4+].[NH4+].[Ni+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DAPUDVOJPZKTSI-UHFFFAOYSA-L 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 229940062331 androgel Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229940054720 avage Drugs 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920003174 cellulose-based polymer Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940041694 estrogel Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000046587 human MAP2 Human genes 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000031539 regulation of cell division Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Psychology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4316397P | 1997-04-10 | 1997-04-10 | |
| US60043163 | 1997-04-10 | ||
| PCT/IB1998/000705 WO1998045322A2 (en) | 1997-04-10 | 1998-04-02 | Diagnosis method and reagents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU7071598A true AU7071598A (en) | 1998-10-30 |
Family
ID=21925819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU70715/98A Abandoned AU7071598A (en) | 1997-04-10 | 1998-04-02 | Diagnosis method and reagents |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0971952A2 (de) |
| JP (1) | JP2001522241A (de) |
| AU (1) | AU7071598A (de) |
| CA (1) | CA2287084A1 (de) |
| WO (1) | WO1998045322A2 (de) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO314086B1 (no) * | 1998-05-08 | 2003-01-27 | Gemvax As | Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til |
| WO2001040804A2 (en) * | 1999-12-03 | 2001-06-07 | Koninklijke Nederlandse Akademie Van Wetenschappen | Clearance of aberrant protein in correlation with disease |
| JP4217613B2 (ja) * | 2001-07-19 | 2009-02-04 | シスメックス株式会社 | Ｐｓ２ｖの検出方法 |
| AU2003253014A1 (en) * | 2002-06-21 | 2004-01-06 | Innogenetics N.V. | Method for the diagnosis and differential diagnosis of neurological diseases |
| JP5116937B2 (ja) | 2003-09-16 | 2013-01-09 | 独立行政法人国立がん研究センター | 哺乳動物由来の検体の癌化度を評価する方法 |
| US7982011B2 (en) | 2003-11-25 | 2011-07-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
| FR2869909B1 (fr) * | 2004-05-04 | 2007-12-21 | Univ Angers | Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire |
| EP1916259A1 (de) | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-Glycoprotein VI SCFV Fragment zur Thrombosebehandlung |
| DK3153526T3 (da) | 2008-01-31 | 2020-12-14 | Inst Nat Sante Rech Med | Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler |
| JP2012504946A (ja) | 2008-10-07 | 2012-03-01 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 血小板第４因子変異体１（ｐｆ４ｖ１）に対する中和抗体およびそのフラグメント |
| WO2010106051A1 (en) | 2009-03-17 | 2010-09-23 | Universite De La Mediterranee | Btla antibodies and uses thereof |
| ES2615881T3 (es) | 2009-05-07 | 2017-06-08 | Stallergenes | Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa. |
| JP2009203240A (ja) * | 2009-06-15 | 2009-09-10 | National Institute Of Advanced Industrial & Technology | リポソームおよびそれからなる細胞への物質導入担体 |
| EP2475398B1 (de) | 2009-09-11 | 2015-05-20 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Verbessertes pseudomonas-exotoxin a mit verminderter immunogenität |
| WO2011080322A1 (en) | 2009-12-30 | 2011-07-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia |
| WO2012010696A1 (en) | 2010-07-23 | 2012-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for cancer management targeting co-029 |
| EP2412724A1 (de) | 2010-07-29 | 2012-02-01 | Centre National de la Recherche Scientifique (C.N.R.S) | Regulierung der Glypican-4-Aktivität zur Modulierung des Schicksals von Stammzellen und Verwendungen davon |
| WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
| EP2654789B1 (de) | 2010-12-22 | 2018-05-30 | Orega Biotech | Antikörper gegen humanes cd39 und ihre verwendung |
| WO2012101125A1 (en) | 2011-01-24 | 2012-08-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific antibodies against human cxcl4 and uses thereof |
| KR101638224B1 (ko) | 2011-02-28 | 2016-07-08 | 에프. 호프만-라 로슈 아게 | 항원 결합 단백질 |
| WO2012131004A2 (en) | 2011-03-31 | 2012-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
| RU2600067C2 (ru) | 2011-05-06 | 2016-10-20 | Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретари Оф Дзе Депармент Оф Хелс Энд Хьюман Сёрвисез | Рекомбинантный иммунотоксин, нацеленный на мезотелин |
| CN103890010B (zh) | 2011-05-19 | 2017-04-19 | 法国国家健康医学研究院 | 抗‑人‑her3抗体及其用途 |
| CN103748107B (zh) | 2011-06-09 | 2020-06-02 | 美利坚合众国, 由健康及人类服务部部长代表 | 具有免疫原性较小的t细胞和/或b细胞表位的假单胞菌外毒素a |
| EP2723376B1 (de) | 2011-06-22 | 2018-12-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl-antikörper und verwendungen damit |
| ES2677367T3 (es) | 2011-06-22 | 2018-08-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticuerpos anti-Axl y usos de los mismos |
| EP3257519B8 (de) | 2011-06-27 | 2020-06-03 | Sorbonne Universite | Ccr2-antagonistenpeptide |
| EP2543677A1 (de) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antikörper zur Behandlung und Vorbeugung von Thrombose |
| EP2543679A1 (de) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antikörper zur Behandlung und Vorbeugung von Thrombose |
| EP2543678A1 (de) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antikörper zur Behandlung und Vorbeugung von Thrombose |
| EP2755993B1 (de) | 2011-09-16 | 2017-11-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen |
| US9676847B2 (en) | 2012-06-25 | 2017-06-13 | Orega Biotech | IL-17 antagonist antibodies |
| EP2892928B1 (de) | 2012-09-03 | 2018-05-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Gegen icos gerichtete antikörper zur behandlung der graft-versus-host-erkrankung |
| AU2013204200B2 (en) * | 2012-10-11 | 2016-10-20 | Brandeis University | Treatment of amyotrophic lateral sclerosis |
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| PE20151603A1 (es) | 2012-12-27 | 2015-11-20 | Sanofi Sa | Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos |
| WO2014183885A1 (en) | 2013-05-17 | 2014-11-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of the btla/hvem interaction for use in therapy |
| WO2014205187A1 (en) | 2013-06-20 | 2014-12-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor |
| EP3038641B1 (de) | 2013-10-06 | 2019-04-17 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Modifiziertes pseudomonas-exotoxin a |
| WO2015067986A1 (en) | 2013-11-07 | 2015-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neuregulin allosteric anti-her3 antibody |
| ES2924393T3 (es) | 2014-04-16 | 2022-10-06 | Inst Nat Sante Rech Med | Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos |
| FR3021970B1 (fr) | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs |
| PT3247725T (pt) | 2015-01-23 | 2020-10-07 | Sanofi Sa | Anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam de forma biespecífica a cd3 e/ou a cd123 |
| WO2016128349A1 (en) | 2015-02-09 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection |
| US20180071413A1 (en) | 2015-04-07 | 2018-03-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Non-invasive imaging of tumor pd-l1 expression |
| EP3319990A1 (de) | 2015-07-07 | 2018-05-16 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Antikörper mit spezifität gegen myosin 18a und verwendungen davon |
| WO2017060397A1 (en) | 2015-10-09 | 2017-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from melanoma metastases |
| BR112018067525A2 (pt) | 2016-02-26 | 2019-02-05 | Centre Nat Rech Scient | anticorpos tendo especificidade para o btla e seus usos |
| JP6899890B2 (ja) * | 2016-03-18 | 2021-07-07 | ジェンクリＧｅｎｃｌｉｓ | アレルギーの分子起源 |
| AU2017277288B2 (en) | 2016-06-09 | 2024-05-16 | Omeros Corporation | Monoclonal antibodies, compositions and methods for detecting mucin -like protein (MLP) as a biomarker for ovarian and pancreatic cancer |
| BR112019001693A2 (pt) | 2016-07-29 | 2019-07-02 | Ct Hospitalier Universitaire Toulouse | anticorpos direcionados a macrófagos associados a tumores e seus usos |
| US11286295B2 (en) | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
| KR101885007B1 (ko) * | 2016-12-22 | 2018-08-31 | 가천대학교 산학협력단 | 인지기능장애의 진단 방법 및 키트 |
| US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
| US11578136B2 (en) | 2017-03-16 | 2023-02-14 | Innate Pharma | Compositions and methods for treating cancer |
| WO2019020480A1 (en) | 2017-07-24 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES |
| MX2020003219A (es) | 2017-09-21 | 2020-07-20 | Imcheck Therapeutics Sas | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. |
| JP7523358B2 (ja) * | 2018-06-13 | 2024-07-26 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | ムスカリン受容体ｍ３に対して阻害活性を有するペプチド |
| EA202092518A1 (ru) | 2018-06-18 | 2021-08-23 | Иннейт Фарма | Композиции и способы лечения рака |
| EP3826669A2 (de) * | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Off-the-shelf-impfstoffe gegen krebs |
| US20220047701A1 (en) | 2018-09-10 | 2022-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of her2/neu antibody with heme for treating cancer |
| AU2020243076A1 (en) | 2019-03-20 | 2021-10-14 | Centre National De La Recherche Scientifique - Cnrs - | Antibodies having specificity for BTN2 and uses thereof |
| JP2022526334A (ja) | 2019-03-25 | 2022-05-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 新たなタウ種を標的化することによるタウオパチー障害の処置の方法 |
| JP2022543259A (ja) | 2019-08-02 | 2022-10-11 | オレガ・バイオテック | 新規ｉｌ－１７ｂ抗体 |
| WO2021058729A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof |
| US20220324962A1 (en) | 2019-09-27 | 2022-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-müllerian inhibiting substance antibodies and uses thereof |
| US20230040928A1 (en) | 2019-12-09 | 2023-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to her4 and uses thereof |
| WO2021175954A1 (en) | 2020-03-04 | 2021-09-10 | Imcheck Therapeutics Sas | Antibodies having specificity for btnl8 and uses thereof |
| MX2022013406A (es) | 2020-04-24 | 2022-11-14 | Sanofi Sa | Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y cetuximab. |
| MX2022013405A (es) | 2020-04-24 | 2022-11-14 | Sanofi Sa | Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y folfox. |
| JP2023522392A (ja) | 2020-04-24 | 2023-05-30 | サノフイ | 抗ｃｅａｃａｍ５抗体コンジュゲートおよびフォルフィリを含有する抗腫瘍組み合わせ |
| WO2021214222A1 (en) | 2020-04-24 | 2021-10-28 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil |
| CN115551553A (zh) | 2020-05-12 | 2022-12-30 | Inserm(法国国家健康医学研究院) | 治疗皮肤t细胞淋巴瘤和tfh起源淋巴瘤的新方法 |
| BR112023001733A2 (pt) | 2020-09-04 | 2023-03-28 | Merck Patent Gmbh | Anticorpos anti-ceacam5 e conjugados e usos dos mesmos |
| WO2022159575A1 (en) | 2021-01-20 | 2022-07-28 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
| WO2023006919A1 (en) | 2021-07-29 | 2023-02-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | HUMANIZED ANTI-HUMAN βIG-H3 PROTEIN AND USES THEREOF |
| IL312519A (en) | 2021-11-05 | 2024-07-01 | Lilly Co Eli | Anticancer combinations containing antibody-drug conjugates anti-CEACAM5 and anti-VEGFR-2 antibodies |
| WO2023150181A1 (en) | 2022-02-01 | 2023-08-10 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
| WO2023170239A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Methods and tools for conjugation to antibodies |
| AU2023230951A1 (en) | 2022-03-09 | 2024-09-05 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
| WO2023240287A1 (en) | 2022-06-10 | 2023-12-14 | Bioentre Llc | Combinations of ctla4 binding proteins and methods of treating cancer |
| WO2024052503A1 (en) | 2022-09-08 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to ltbp2 and uses thereof |
| WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
| WO2024180192A1 (en) | 2023-03-01 | 2024-09-06 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5 |
| EP4427763A1 (de) | 2023-03-06 | 2024-09-11 | Sanofi | Antitumorkombinationen mit anti-ceacam5-antikörper-wirkstoff-konjugaten, anti-vegfr-2-antikörpern und anti-pd1/pd-l1-antikörpern |
| WO2024194455A1 (en) | 2023-03-23 | 2024-09-26 | Sanofi | CEACAM5 mRNA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8718779D0 (en) * | 1987-08-07 | 1987-09-16 | Grosveld F G | Dna sequence & expression vector |
| US5015570A (en) * | 1988-05-13 | 1991-05-14 | Molecular Therapeutics, Inc. | Molecular diagnosis of Alzheimer Disease |
| EP0451700A1 (de) * | 1990-04-10 | 1991-10-16 | Miles Inc. | Rekombinante APP Minigene zur Expression in Transgen-Mäusen als Alzheimer-Krankheitsmuster |
| US5455169A (en) * | 1992-06-04 | 1995-10-03 | Alzheimer's Institute Of America, Inc. | Nucleic acids for diagnosing and modeling Alzheimer's disease |
| AU4769893A (en) * | 1992-07-17 | 1994-02-14 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| US5854392A (en) * | 1992-08-31 | 1998-12-29 | Bristol-Myers Squibb Company | β APP-C100 receptor |
| US5449604A (en) * | 1992-10-21 | 1995-09-12 | University Of Washington | Chromosome 14 and familial Alzheimers disease genetic markers and assays |
| GB9410922D0 (en) * | 1994-06-01 | 1994-07-20 | Townsend Alain R M | Vaccines |
| US5958684A (en) * | 1995-10-02 | 1999-09-28 | Van Leeuwen; Frederik Willem | Diagnosis of neurodegenerative disease |
-
1998
- 1998-04-02 WO PCT/IB1998/000705 patent/WO1998045322A2/en not_active Application Discontinuation
- 1998-04-02 EP EP98917502A patent/EP0971952A2/de not_active Withdrawn
- 1998-04-02 AU AU70715/98A patent/AU7071598A/en not_active Abandoned
- 1998-04-02 JP JP54254598A patent/JP2001522241A/ja active Pending
- 1998-04-02 CA CA002287084A patent/CA2287084A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0971952A2 (de) | 2000-01-19 |
| JP2001522241A (ja) | 2001-11-13 |
| WO1998045322A2 (en) | 1998-10-15 |
| CA2287084A1 (en) | 1998-10-15 |
| WO1998045322A3 (en) | 1999-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU7071598A (en) | Diagnosis method and reagents | |
| US5958684A (en) | Diagnosis of neurodegenerative disease | |
| JP3220752B2 (ja) | Ｍｔｓ−１遺伝子により転移性癌の診断 | |
| US7041291B2 (en) | Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor | |
| JP2007524583A (ja) | 自己免疫異常に関わるｈｌａ−ｄｒｍｈｃクラスｉｉ分子に関するペプチド | |
| CA2093735A1 (en) | Amyloid precursor-like protein and uses thereof | |
| JP2005218453A (ja) | ８７個のヒト分泌タンパク質 | |
| JP2008505608A (ja) | Ｍｅｃｐ２ｅ１遺伝子 | |
| JP5997104B2 (ja) | 新規治療用および診断用生成物および方法 | |
| US5756348A (en) | DNA encoding a glycine transporter and uses thereof | |
| JPH08509808A (ja) | 神経糸状タンパク質遺伝子発現およびアルツハイマー病の検出 | |
| US6617131B2 (en) | Nucleic acid molecule encoding the potassium channel protein, KCNQ5 | |
| JP2007535562A (ja) | 多嚢胞性疾患の処置のための方法および組成物 | |
| JP2003524366A (ja) | ６４個のヒト分泌タンパク質 | |
| EP1187853B1 (de) | Diagnostische verwendungen von gegen acetylcholinesterase oder deren c-terminale peptide gerichteten antikörpern | |
| JP2008504270A (ja) | 嚢胞性疾患を処置するための方法および組成物 | |
| US7211649B1 (en) | Cartilage intermediate layer protein | |
| US20030013087A1 (en) | Novel mutations in the freac3 gene for diagnosis and prognosis of glaucoma and anterior segment dysgenesis | |
| WO2001046415A1 (fr) | Polypeptides de type tachykinine et utilisation associee | |
| JP2001501802A (ja) | ハンチンチン（ｈｕｎｔｉｎｇｔｉｎ）結合蛋白質 | |
| JP2004057180A (ja) | 変異アンドロゲン受容体、それを発現する癌細胞、それらの作出方法およびそれらの用途 | |
| KR20010030862A (ko) | 프리세닐린과 상호작용할 수 있는 단백질을 암호화하는 핵산 | |
| US5763216A (en) | Gene encoding a human reduced folate carrier (RFC) | |
| US7592424B2 (en) | Ion channel-like polypeptide and use thereof | |
| JP2006525244A (ja) | 糖尿病の治療標的としてのインスリン誘導性遺伝子 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |